CY1121787T1 - Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων - Google Patents

Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων

Info

Publication number
CY1121787T1
CY1121787T1 CY20191100658T CY191100658T CY1121787T1 CY 1121787 T1 CY1121787 T1 CY 1121787T1 CY 20191100658 T CY20191100658 T CY 20191100658T CY 191100658 T CY191100658 T CY 191100658T CY 1121787 T1 CY1121787 T1 CY 1121787T1
Authority
CY
Cyprus
Prior art keywords
prevention
compositions
treatment
methods
sirna
Prior art date
Application number
CY20191100658T
Other languages
English (en)
Inventor
Marta Lopez-Fraga
Ana Isabel Jimenez
Tamara Martinez Valcarel
Original Assignee
Sylentis S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis S.A.U. filed Critical Sylentis S.A.U.
Publication of CY1121787T1 publication Critical patent/CY1121787T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά σε μεθόδους και συνθέσεις για τη θεραπεία ή/και πρόληψη οφθαλμικών καταστάσεων που σχετίζονται με υψηλά επίπεδα έκφρασης ή/και δραστικότητας του βανιλλοειδούς-1 υποδοχέα (TRVP).
CY20191100658T 2010-05-27 2019-06-26 Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων CY1121787T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10380074A EP2390327A1 (en) 2010-05-27 2010-05-27 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP11723600.0A EP2576782B1 (en) 2010-05-27 2011-05-27 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
PCT/GB2011/051007 WO2011148193A1 (en) 2010-05-27 2011-05-27 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
CY1121787T1 true CY1121787T1 (el) 2020-07-31

Family

ID=42829386

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100658T CY1121787T1 (el) 2010-05-27 2019-06-26 Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων

Country Status (20)

Country Link
US (1) US9018183B2 (el)
EP (2) EP2390327A1 (el)
JP (2) JP6008845B2 (el)
KR (1) KR101585036B1 (el)
CN (1) CN102918157B (el)
AU (1) AU2011256978B2 (el)
CA (1) CA2800412C (el)
CY (1) CY1121787T1 (el)
DK (1) DK2576782T3 (el)
ES (1) ES2732351T3 (el)
HR (1) HRP20191144T1 (el)
HU (1) HUE044715T2 (el)
LT (1) LT2576782T (el)
MX (1) MX2012012501A (el)
PL (1) PL2576782T3 (el)
PT (1) PT2576782T (el)
RS (1) RS58912B1 (el)
SI (1) SI2576782T1 (el)
TR (1) TR201909158T4 (el)
WO (1) WO2011148193A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113430196A (zh) 2011-06-30 2021-09-24 箭头药业股份有限公司 用于抑制乙型肝炎病毒的基因表达的组合物和方法
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
EP2865756A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
MA44908A (fr) * 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4095895B2 (ja) 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
EP2258847B2 (en) 2002-08-05 2020-07-01 Silence Therapeutics GmbH Futher novel forms of interfering RNA molecules
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
WO2008104978A2 (en) 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
US20110160279A1 (en) * 2007-08-13 2011-06-30 Board Of Trustees Of Southern Illinois University METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA
BRPI0817605A2 (pt) 2007-10-03 2017-05-09 Quark Pharmaceuticals Inc novas estruturas de sirna

Also Published As

Publication number Publication date
KR20130043121A (ko) 2013-04-29
JP6008845B2 (ja) 2016-10-19
RS58912B1 (sr) 2019-08-30
JP2016198104A (ja) 2016-12-01
PL2576782T3 (pl) 2019-09-30
JP2013528382A (ja) 2013-07-11
SI2576782T1 (sl) 2019-08-30
MX2012012501A (es) 2013-02-26
ES2732351T3 (es) 2019-11-22
TR201909158T4 (tr) 2019-07-22
US20130079389A1 (en) 2013-03-28
CA2800412C (en) 2019-09-17
HRP20191144T1 (hr) 2019-10-04
KR101585036B1 (ko) 2016-01-13
EP2390327A1 (en) 2011-11-30
LT2576782T (lt) 2019-07-10
EP2576782A1 (en) 2013-04-10
CN102918157B (zh) 2016-06-29
AU2011256978A1 (en) 2012-11-15
CA2800412A1 (en) 2011-12-01
AU2011256978B2 (en) 2015-06-11
CN102918157A (zh) 2013-02-06
PT2576782T (pt) 2019-06-28
DK2576782T3 (da) 2019-07-01
WO2011148193A1 (en) 2011-12-01
EP2576782B1 (en) 2019-03-27
US9018183B2 (en) 2015-04-28
HUE044715T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1125436T1 (el) Αναστολεις dna-pk
CY1124474T1 (el) Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
EA201492289A1 (ru) Композиции, содержащие аптамер против pdgf и антагонист vegf
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
EA201592225A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
UY34472A (es) Derivados modificados de 4-fenil-piridina
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
CY1123718T1 (el) Κυτταροκαλλιεργεια
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
CY1120906T1 (el) Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
CY1116318T1 (el) Μακροκυκλικη ενωση και μεθοδοι για την παραγωγη της
CY1117458T1 (el) Αγωνιστες αδενοσινης α1 για τη θεραπευτικη αντιμετωπιση του γλαυκωματος και της οφθαλμικης υπερτασης
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.